Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Axsome Thera (AXSM)

Axsome Thera (AXSM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Axsome Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire - Wed Feb 25, 6:00AM CST

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 160.50 (+2.65%)
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms GlobeNewswire - Tue Feb 24, 6:00AM CST

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 160.50 (+2.65%)
Axsome: Q4 Earnings Snapshot AP - Mon Feb 23, 8:47AM CST

Axsome: Q4 Earnings Snapshot

AXSM : 160.50 (+2.65%)
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update GlobeNewswire - Mon Feb 23, 6:00AM CST

Total 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% year-over-year growth   AUVELITY ® 4Q and full year 2025 net...

AXSM : 160.50 (+2.65%)
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference GlobeNewswire - Wed Feb 18, 6:00AM CST

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 160.50 (+2.65%)
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd. GlobeNewswire - Tue Feb 17, 6:00AM CST

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders,...

AXSM : 160.50 (+2.65%)
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 GlobeNewswire - Tue Jan 27, 6:00AM CST

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 160.50 (+2.65%)
Medical Laboratory by Gorodenkoff via Shutterstock
MoneyShow Top Picks 2026: Axsome Therapeutics Inc. (AXSM) MoneyShow - Fri Jan 23, 8:18AM CST

Axsome Therapeutics Inc. (AXSM) is a name we started to follow just as the market was going over the falls in early 2025, advises Mike Cintolo, chief investment strategist at Cabot Wealth Network.

AXSM : 160.50 (+2.65%)
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia GlobeNewswire - Thu Jan 15, 6:00AM CST

NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 160.50 (+2.65%)
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue GlobeNewswire - Mon Jan 12, 6:00AM CST

Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively  AUVELITY ® preliminary...

AXSM : 160.50 (+2.65%)

Barchart Exclusives

Meta Platforms Just Made Entergy a Top Stock to Buy... and It Pays a 2.49% Dividend Barchart - Mon Mar 30, 6:30PM CDT
Meta’s decision to fully fund seven new natural gas plants, 240 miles of 500 kV transmission, batteries, and up to 2.5 GW of solar to power its giant Louisiana AI data center effectively gives Entergy a multi‑decade growth runway with limited bill pressure on other customers, which is a rare setup for a regulated utility. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.